drugset / Trial / NCT02171832
Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The main objective of this study was to investigate the influence of mild and moderate liver impairment on the pharmacokinetics, safety and selected pharmacodynamic parameters of BI 1744 CL in comparison to a control group with normal hepatic function after single orally inhaled administration of BI 1744 CL with the Respimat® Inhaler.
Timeline
- Start
- 2009-07
- Primary completion
- 2009-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olodaterol | Small molecule | 20 ug | Inhaled |
| Subject | Olodaterol | Small molecule | 30 ug | Inhaled |